Getinge’s decision to leave the surgical perfusion market will benefit LivaNova, an already dominant player in the sector ...

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Barclays Global ...

GlobalData’s latest report reveals global CBPE market expected to grow at a CAGR of 1.2 per cent from $508.2 million in 2024 ...

LivaNova’s LIVN OSPREY trial, evaluating the aura6000 nerve stimulation system for obstructive sleep apnea (OSA), has delivered promising results.By meeting primary safety and efficacy endpoints ...

LivaNova has a 12 month low of $43.15 and a 12 month high of $64.47. The company has a market capitalization of $2.59 billion, a price-to-earnings ratio of 113.52 and a beta of 1.00.

LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare ...

Greenlight Capital highlighted stocks like LivaNova PLC (NASDAQ:LIVN) in the fourth quarter 2024 investor letter. Headquartered in London, the United Kingdom, LivaNova PLC (NASDAQ:LIVN ...

So when we looked at LivaNova (NASDAQ:LIVN) and its trend of ROCE, we really liked what we saw. For those that aren't sure what ROCE is, it measures the amount of pre-tax profits a company can ...